November 1, 2010 |
Nancy Kaneshiro tried practically every popular weight-loss program in the 1990s, including Weight Watchers and Jenny Craig. But the fortysomething book publicist remained 100 pounds overweight. When diagnosed with diabetes in 1998, "I flipped my wig," she said. Her internist started her on the diabetes drugs metformin, glipizide and Actos. The Woodland Hills resident became a zealous calorie-counter and gym-goer, doing 30 to 60 minutes of cardio and resistance training at her 24 Hour Fitness every morning for 10 years.
November 1, 2010 |
For people with Type 2 diabetes, diet and exercise often aren't enough to keep blood sugar levels in a healthy range. That's where medication comes in. Metformin typically is the first choice for a diabetic patient beginning drug treatment. It's been around for decades (and marketed in the U.S. for 15 years) and is considered a very safe drug. Other advantages include the fact that it doesn't cause weight gain ? as do some other diabetes medications. Plus it's generic and thus cheaper, says Dr. Andrew Drexler, director of the Gonda Diabetes Center at UCLA.
November 3, 2010 |
Researchers have been looking at the ways lifestyle affects Type 2 diabetes. Here's what they've found: What: In 2002, the National Institutes of Health published results from the landmark Diabetes Prevention Program study in the New England Journal of Medicine. In the trial, 3,234 overweight people at risk of developing Type 2 diabetes were split into three groups to test whether lifestyle changes or the drug metformin could prevent the onset of diabetes. ? Group 1 received extensive training in diet and exercise, with goals of exercising 150 minutes per week and losing and keeping off 7% of their body weight.
August 2, 2000 |
The Food and Drug Administration on Tuesday approved Bristol-Myers Squibb's new diabetes drug Glucovance, which may help patients control their blood sugar better than some existing pills. The approval comes at an opportune moment for Bristol-Myers, which next month will lose patent protection on its top diabetes drug, Glucophage. The pill, with $1.3 billion in sales last year, is the company's top-selling medicine.
September 17, 2008 |
The government closed U.S. borders Tuesday to more than 30 generic drugs -- including popular antibiotics and cholesterol medicines -- made by India's biggest pharmaceutical company, citing poor quality in two of its factories. The Food and Drug Administration's move doesn't end U.S. sales by Ranbaxy Laboratories Ltd. Instead, it blocks imports of generic drugs -- including generic versions of the antibiotic Cipro and the cholesterol pill Zocor -- as well as pharmaceutical ingredients made at the suspect plants.
March 30, 1998
A combination of two new diabetes drugs has proved a powerful means of controlling hard-to-treat cases of the disease. The drugs are troglitazone, approved by the Food and Drug Administration last year, and metformin, approved two years ago. Both are for adult onset diabetes, a disease of high blood sugar that afflicts millions of Americans.
October 18, 2006 |
Federal regulators Tuesday approved a new class of oral drugs for Type 2 diabetes that is as effective as most existing treatments and avoids common side effects, such as dangerously low blood sugar. The Food and Drug Administration said that Merck & Co.'s Januvia, a once-daily tablet, could be taken alone or in combination with the common oral diabetes medicines metformin, Actos and Avandia. Dr.
October 26, 2009 |
Medications for Type 2 (adult-onset) diabetes are very effective at controlling blood sugar levels. You'd think, then, that the drugs would also be very effective at controlling complications of the disease related to those spikes in blood sugar: cardiovascular disease, kidney failure, blindness, nerve damage and amputation of limbs. Surprisingly, though, that has not turned out to be the case for cardiovascular events such as heart attacks and strokes. One study, in fact, hints that too-tight control may even cause patients harm.
January 8, 2014 |
The Food and Drug Administration on Wednesday approved U.S. marketing of the drug dapagliflozin, the second of a new class of medications that aim to improve glycemic control in patients with Type 2 diabetes. The drug will be marketed under the name Farxiga. Dapagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor, a drug that blocks the reabsorption of glucose by the kidney, increases the excretion of glucose in urine and lowers glucose levels in the blood. It will join -- and is likely to be prescribed in conjunction with -- a wide range of diabetes medications, including metformin, pioglitazone, glimepiride, sitagliptin and insulin.
November 17, 2003 |
Facial hair and obesity in adolescent girls often are caused by a complex condition diagnosed only years later when the girls-turned-women discover another symptom: They can't get pregnant. The baffling disorder, called polycystic ovarian syndrome, is caused by the production of too many androgen hormones, such as testosterone. One of the leading causes of infertility, it affects an estimated 6% to 10% of U.S. women to varying degrees, though most are never diagnosed.